The Company (Details) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 06, 2017	Jun. 30, 2017 USD ($) shares	Jun. 30, 2016 USD ($) shares	Jun. 30, 2017 USD ($) Systems Extension shares	Jun. 30, 2016 USD ($) shares	Dec. 31, 2016 USD ($)
Business Acquisition [Line Items]
Reverse stock-split ratio	0.20
Liquidity [Abstract]
Accumulated deficit		$ (214,015)		$ (214,015)		$ (210,575)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt		21,503		21,503		20,082
Earnings Per Share [Abstract]
Net income (loss)			$ 498		$ (939)
Gain on the change in fair value of the warrant liability		$ (128)	(3,199)	$ 4	(5,184)
Diluted earnings			$ (2,701)		$ (6,123)
Weighted average number of common and common equivalent shares outstanding [Abstract]
Basic number of common shares outstanding (in shares) | shares		2,327,041	2,117,897	2,252,301	2,092,914
Dilutive effect of warrants (in shares) | shares			193,150		123,267
Diluted number of common and common stock equivalent shares outstanding (in shares) | shares		2,327,041	2,311,047	2,252,301	2,216,181
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				12,625,847	13,676,039
Ellipse [Member]
Business Acquisition [Line Items]
License agreement, number of additional years automatically extended				2 years
Monthly license fee				$ 33
License fee for initial term				$ 1,100
Esthetic Education, LLC [Member]
Business Acquisition [Line Items]
Agreement period				3 years
Number of extensions allowed | Extension				2
Period of extension				1 year
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		$ 109		$ 109		105
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		0		0		0
Fair Value, Measurements, Recurring [Member] | Significant other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		0		0		0
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		$ 109		$ 109		$ 105
XTRAC [Member]
Business Acquisition [Line Items]
Number of systems placed in dermatologists offices | Systems				795
Common Stock Equivalents of Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				9,146,146	9,221,143
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				2,406,625	3,345,873
Common Stock Equivalents of Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				228,336	507,173
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				844,740	601,850